Fischer PM - Search Results

1

Progress in the discovery of polo-like kinase inhibitors.

McInnes C, Mezna M, Fischer PM. McInnes C, et al. Among authors: fischer pm. Curr Top Med Chem. 2005;5(2):181-97. doi: 10.2174/1568026053507660. Curr Top Med Chem. 2005. PMID: 15853646 Review.

2

Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.

Fischer PM, Lane DP. Fischer PM, et al. Curr Med Chem. 2000 Dec;7(12):1213-45. doi: 10.2174/0929867003374048. Curr Med Chem. 2000. PMID: 11032968

3

Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: structural variants of the C-terminal Phe.

Atkinson GE, Cowan A, McInnes C, Zheleva DI, Fischer PM, Chan WC. Atkinson GE, et al. Among authors: fischer pm. Bioorg Med Chem Lett. 2002 Sep 16;12(18):2501-5. doi: 10.1016/s0960-894x(02)00508-5. Bioorg Med Chem Lett. 2002. PMID: 12182847

4

Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.

Zheleva DI, McInnes C, Gavine AL, Zhelev NZ, Fischer PM, Lane DP. Zheleva DI, et al. Among authors: fischer pm. J Pept Res. 2002 Nov;60(5):257-70. doi: 10.1034/j.1399-3011.2002.21014.x. J Pept Res. 2002. PMID: 12383116

5

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine).

McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, Lane DP. McClue SJ, et al. Among authors: fischer pm. Int J Cancer. 2002 Dec 10;102(5):463-8. doi: 10.1002/ijc.10738. Int J Cancer. 2002. PMID: 12432547

6

Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.

McInnes C, Andrews MJ, Zheleva DI, Lane DP, Fischer PM. McInnes C, et al. Among authors: fischer pm. Curr Med Chem Anticancer Agents. 2003 Jan;3(1):57-69. doi: 10.2174/1568011033353506. Curr Med Chem Anticancer Agents. 2003. PMID: 12678915 Review.

7

Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop.

Wu SY, McNae I, Kontopidis G, McClue SJ, McInnes C, Stewart KJ, Wang S, Zheleva DI, Marriage H, Lane DP, Taylor P, Fischer PM, Walkinshaw MD. Wu SY, et al. Among authors: fischer pm. Structure. 2003 Apr;11(4):399-410. doi: 10.1016/s0969-2126(03)00060-1. Structure. 2003. PMID: 12679018 Free article.

8

The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics.

Zheleva DI, Lane DP, Fischer PM. Zheleva DI, et al. Among authors: fischer pm. Mini Rev Med Chem. 2003 May;3(3):257-70. doi: 10.2174/1389557033488178. Mini Rev Med Chem. 2003. PMID: 12698949 Review.

9

CDK inhibitors in clinical development for the treatment of cancer.

Fischer PM, Gianella-Borradori A. Fischer PM, et al. Expert Opin Investig Drugs. 2003 Jun;12(6):955-70. doi: 10.1517/13543784.12.6.955. Expert Opin Investig Drugs. 2003. PMID: 12783600 Review.

10

Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.

Fischer PM. Fischer PM. Curr Opin Drug Discov Devel. 2001 Sep;4(5):623-34. Curr Opin Drug Discov Devel. 2001. PMID: 12825457 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

200 results

Search Page

Filters